Xencor Partners with Merck in Antibody Technology - The partnership provides access to Xencor’s Fc engineering patents for monoclonal antibodies. - BioPharm International

ADVERTISEMENT

Xencor Partners with Merck in Antibody Technology
The partnership provides access to Xencor’s Fc engineering patents for monoclonal antibodies.


Xencor, a biopharmaceutical company specializing in antibody engineering technology, has entered into a technology license and option agreement to provide Merck & Co. access to one of Xencor’s Fc engineering patents for a therapeutic monoclonal antibody.

Under the agreement, Merck will be granted a nonexclusive license to a Xencor patent for use in an undisclosed product as well as an option to license the same intellectual property for future products. Xencor will receive an upfront payment and annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates as well as royalties on sales of any potential products that may result from this agreement, according to a Xencor statement.

Xencor engineers biotherapeutics using its proprietary Protein Design Automation technology platform, which is used in antibody engineering to improve antibody half-life, immune-regulatory function, and potency. The company is advancing multiple proprietary XmAb antibody drug candidates in the clinic, including XmAb5871 targeting CD32b and CD19 for autoimmune diseases, and the anti-CD30 candidate XmAb2513 for the treatment of Hodgkin’s lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbuster antibody drugs engineered for improved half-life and dosing schedules. Xencor has partnerships with Amgen, Pfizer, Janssen R&D, MorphoSys, Boehringer Ingelheim, CSL, and Human Genome Sciences (now part of GlaxoSmithKline). In these partnerships, Xencor is applying its proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency, according to company information.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here